Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26790756 | 0.76 | EGLN2 (0.41) | TGFBR1PIK3CDTNIKBACE1KDM1A | |
| SCHEMBL25251508 | 0.72 | OGA (0.39) | PIK3CDGRM5 | |
| SCHEMBL23432223 | 0.70 | TGFBR1 (0.40) | TGFBR1PIK3CDTNIKBACE1 | |
| SCHEMBL1990408 | 0.67 | PDE10A (0.35) | — | |
| SCHEMBL1192186 | 0.66 | TGFBR1 (0.37) | TGFBR1PIK3CDTNIKBACE1 | |
| SCHEMBL24167389 | 0.66 | TGFBR1 (0.37) | TGFBR1PIK3CDTNIKBACE1 | |
| SCHEMBL619814 | 0.66 | AHR (0.43) | TGFBR1PIK3CDTNIKBACE1 | |
| SCHEMBL12650423 | 0.66 | MET (0.41) | TGFBR1PIK3CDTNIKBACE1 | |
| SCHEMBL6371587 | 0.66 | PIK3CD (0.36) | TGFBR1PIK3CDTNIKBACE1 | |
| SCHEMBL21646380 | 0.66 | MAP4K4 (0.42) | TGFBR1PIK3CDTNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | TGFBR1 406/4885PIK3CD 383/4885FGFR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.